Catamaran Corp (CTRX): Today's Featured Health Care Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Catamaran ( CTRX) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 0.5%. By the end of trading, Catamaran rose $0.53 (1.1%) to $48.21 on heavy volume. Throughout the day, 2,306,189 shares of Catamaran exchanged hands as compared to its average daily volume of 1,384,600 shares. The stock ranged in a price between $47.67-$48.61 after having opened the day at $47.86 as compared to the previous trading day's close of $47.68. Other companies within the Health Care sector that increased today were: MAKO Surgical Corporation ( MAKO), up 82.2%, Pacific Biosciences of California ( PACB), up 72.8%, GW Pharmaceuticals PLC ADR ( GWPH), up 63.1% and Oncothyreon ( ONTY), up 21.1%.

Catamaran Corporation provides pharmacy benefit management (PBM) services and healthcare information technology (HCIT) solutions to the healthcare benefits management industry in North America. The company operates in two segments: PBM and HCIT. Catamaran has a market cap of $9.9 billion and is part of the health services industry. Shares are up 1.7% year to date as of the close of trading on Tuesday. Currently there are 11 analysts that rate Catamaran a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Catamaran as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, compelling growth in net income and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.

On the negative front, Genvec ( GNVC), down 16.7%, KaloBios Pharmaceuticals ( KBIO), down 15.2%, AMAG Pharmaceuticals ( AMAG), down 14.3% and Clovis Oncology ( CLVS), down 11.6% , were all laggards within the health care sector with Baxter International ( BAX) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%